Document:

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

MANAGEMENT SERVICES AGREEMENT

 

TABLE OF CONTENTS

 

	Section	 	 
	1	 	Term   
	2	 	Exclusivity                
	3	 	Argus Services       
	4	 	Information Obtained through Argus Services
	5	 	Systems, Data and Security
	6	 	Customer’s Payment of Argus’ Invoices
	7	 	Mutual Cooperation and Testing
	8	 	Performance Warranty
	9	 	Limitation of Liability  
	10	 	Indemnity   
	11	 	Termination  
	12	 	Confidentiality    
	13	 	Ownership
	14	 	Audits/Subpoenas
	15	 	Force Majeure
	16	 	Compliance with Laws
	17	 	Miscellaneous Legal Provisions
	Exhibit A	 	Definitions
	Exhibit B	 	Liability Limit Calculation
	Exhibit C	 	Fees and Expenses

 

 

Service Exhibits:

 

	Exhibit D	Claims Processing and Related Services
	Exhibit E	Pharmacy Network Services
	Exhibit F	Targeted Intervention Strategies
	Exhibit G	PaHub Automated Authorization Services
	Exhibit H	Predictive Modeling (ACG® Pharmacy Predictive Model)

 

Appendices (Forms/Catalog Listings):

 

	Appendix 1	Form of Argus Networks

 

Regulatory Addenda:

 

Privacy/Security Regulatory Addendum

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 1

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

  

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

 

THIS MANAGEMENT
SERVICES AGREEMENT (“MSA”), effective as of this 1st day of January, 2012 (“Effective Date”), is between
Argus Health Systems, Inc., a Delaware corporation having its principal place of business at 1300 Washington Street, Kansas City,
Missouri 64105-1433 (“Argus”), and Healthcare Corporation of America – Prescription Corporation of America, Inc.,
having its principal place of business at 66 Ford Road, Suite 230

Denville, New Jersey 07843 (“Customer”).

 

The capitalized terms
used herein are defined in the body of this MSA (including exhibits, appendices, and addenda) or in Exhibit A (Definitions), attached
hereto and incorporated herein by reference.

 

WHEREAS, Argus
is in the business of providing certain services (discussed in greater detail in the Service Exhibits) that support the pharmaceutical
industry.

 

WHEREAS, Customer
desires to utilize such services and is willing to compensate Argus as outlined in this MSA.

 

NOW, THEREFORE,
in consideration of the mutual covenants and agreements contained herein, the sufficiency and adequacy of which are hereby acknowledged,
the parties hereby agree as follows:

 

1.TERM.

 

A.
Initial Term. This MSA shall remain in full force and effect for a period of three (3) years from the Effective Date.

 

B.
Renewal. This MSA shall be automatically renewed for successive three-year periods unless either party gives the other
party at least ninety (90) days written notice of non-renewal prior to the end of the then-current term.

 

2.EXCLUSIVITY. Except as provided
herein, during the term of this MSA: (a) Customer shall exclusively utilize Argus for the type of services that the parties have
agreed Argus is to provide hereunder; and (b) Argus may provide such services to third parties.

 

3.ARGUS SERVICES.  Argus shall
provide to Customer the services set forth in each of the Exhibits attached hereto and incorporated herein by reference (collectively,
the “Service Exhibits”), subject to the regulatory obligations set forth in the Regulatory Addendum (Miscellaneous)
attached hereto and incorporated herein by reference.

 

4.INFORMATION OBTAINED THROUGH ARGUS
SERVICES. Customer acknowledges and agrees that (a) information in Argus databases is derived from third party sources and
is not independently developed by Argus, and Argus utilizes industry materials and the advice and resources of outside vendors
and healthcare professionals to provide Argus services, (b) the usefulness of the information provided by Argus is necessarily
limited by the amount of information received by Argus from Customer and others, and the thoroughness and accuracy of such information,
(c) Argus’ databases do not contain all currently available information on healthcare or pharmaceutical practices, (d)
Argus is not responsible for failing to include information in databases that is not specifically requested by Customer or required
by this MSA, for the actions or omissions of contributors of information to Argus or for misstatements or inaccuracies in industry
materials utilized by Argus, and (e) all warranty disclaimers and exclusions made by contributors of information or data to Argus
shall apply to the Argus services provided hereunder.  

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 2

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

 

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

 

5.SYSTEMS, DATA AND SECURITY 

 

A.Access
to Systems. With respect to each service Argus is to provide to Customer allowing Customer access to an Argus system or database,
Argus shall provide Customer with Access Information. If Argus requires, Customer shall inform Argus of the identity of authorized
users, of additions and deletions to the list of users, and of access rights of individual users and shall ensure that Access
Information is not provided to users not designated to Argus. Passwords will expire periodically, which will require entry of
a new password for each user on a regular interval defined by Argus. Customer shall provide at its expense, the equipment, software
and communications network transmission capabilities necessary to access Argus databases and systems.

 

B.Customer
Data Provided for Input. If Customer is providing data to Argus, Customer shall maintain in an uncorrupted condition and have
available backup copies of all such data and information and Argus shall have no obligation to reconstruct or recompile such data.

 

C.Internet
Security. Customer acknowledges that the Internet is not a secure or reliable environment and that the ability of Argus to
deliver Internet services is dependent upon the Internet and equipment, software, systems, data and services provided by various
telecommunications carriers, equipment manufacturers, firewall providers and encryption system developers and other vendors and
third-parties. Customer acknowledges that use of the Internet in conjunction with Argus’ services entails confidentiality
and other risks that may be beyond Argus’ reasonable control. Argus agrees to maintain and make available written and HIPAA
compliant encryption and other protocols to protect against unauthorized interception, corruption, use of or access to Proprietary
Information that it receives and/or disseminates over the Internet (“Internet Protocol”). Argus may, but shall not
be required to, modify the Internet Protocol from time to time to the extent it believes in good faith that such modifications
will not diminish the security of Argus’ systems.

 

6.CUSTOMER'S
PAYMENT OF ARGUS’ INVOICES. 

 

A.Fees
and Expenses. Customer acknowledges and agrees that it has carefully reviewed Exhibit C (Fees
and Expenses) attached hereto and incorporated herein by reference, and shall pay all
charges and fees set forth therein for services Customer has selected as of the Effective Date and for Argus’ expenses,
including without limitation those expenses set forth in Exhibit C. For services not selected by Customer at the Effective Date
but later selected by Customer (“Additional Services”), Customer shall pay Argus at Argus’ then current rates
for such Additional Services or at such other rates as are reflected in a modified Exhibit C to which Argus and Customer
have agreed in writing prior to the rendering of the Additional Services.

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 3

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

 

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

 

B.
Disputed Amounts and Late Fees. Customer shall pay Argus within fifteen (15) calendar days
of the receipt of each invoice from Argus (the “Invoice Payment Date”), except such amounts as are disputed in good
faith by providing adequate written notice and documentation of such dispute to Argus no later than the Invoice Payment Date.
Customer shall work diligently with Argus to promptly resolve such dispute. Within fifteen (15) calendar days of the resolution
of such dispute (the “Dispute Payment Date”), Customer shall remit to Argus the agreed-upon amount. For any amounts
that are due hereunder and are not received by Argus by the Invoice Payment Date or the Dispute Payment Date, Customer shall pay
to Argus a late charge equal to an annual interest rate of eighteen percent (18.0%) until such amounts are paid in full. Customer
shall reimburse Argus for its reasonable expenses, including attorneys’ fees, in enforcing this Section 6.

 

C.Disbursements to Contracted
Pharmacies. This Section does not apply to Customer’s obligation to fund Disbursements, which is covered in Exhibit D
(Claims Processing and Related Services).

 

7.MUTUAL COOPERATION
AND TESTING. 

 

A.Cooperation.
Each party shall reasonably cooperate with the other party during the implementation of services and throughout the term of this
MSA as necessary for the performance of the parties’ respective obligations hereunder. As soon as necessary for Argus to
fulfill its obligations under this MSA, and otherwise within a reasonable period of time, Customer shall respond to any requests
by Argus for information or determinations needed by Argus to perform the services set forth herein. Customer shall provide to
Argus valid, correct, properly formatted and transmitted data and any other information necessary for Argus to fulfill its obligations
to Customer. Customer shall advise Argus of any Argus error, failure in performance, or inconsistency within a prompt period of
time after discovery and in any event no later than the earlier of one (1) year from the occurrence or sixty (60) days after termination
or expiration of the Agreement.

 

B.
Testing. When Customer and Argus have agreed that Customer shall conduct testing of or review
the testing results of a process or method, Customer shall have an obligation to promptly notify Argus of any error in the process
or method, and Argus shall have no responsibility to make adjustments with respect to and shall not be liable for errors about
which Customer failed to give such notice to Argus upon testing. 

 

8.PERFORMANCE
WARRANTY. 

 

A.Warranty.
Argus shall at all times use reasonable commercial efforts to fulfill its obligations under the Service Exhibits; provided, however,
that Argus’ commercial efforts shall not be deemed unreasonable to the extent Argus’ ability to perform was affected
by Customer’s breach of its obligations hereunder or Argus was complying with Customer’s instructions.

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 4

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

 

B.Re-Performance
Obligations. In the event of any claim by Customer that Argus has not performed its obligations
to provide services as required by this MSA, the sole obligation of Argus, if available, shall be to re-perform within commercially
reasonable limits any service which does not conform to this MSA at Argus’ expense, provided that such failure to perform
is not due to an act or omission by Customer. 

 

Argus shall make
reasonable efforts, in its sole discretion, to collect any overpayments from Participating Pharmacies; however, Argus shall not
be required to institute any litigation or other legal action or proceeding to collect any overpayments. Argus' obligation to attempt
reasonable collection efforts shall be Argus' sole obligation and liability with respect to remedying such overpayments.

 

C.Disclaimers.
EXCEPT AS PROVIDED IN THIS SECTION 9, NOTWITHSTANDING ANY OTHER TERM OF THIS MSA, ARGUS’ SERVICES AND ALL SYSTEMS AND
DATABASES DESCRIBED IN THIS MSA ARE PROVIDED “AS-IS” ON AN “AS AVAILABLE” BASIS, AND ARGUS SPECIFICALLY
DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, REGARDING SERVICES PROVIDED HEREUNDER, INCLUDING WITHOUT
LIMITATION THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, AND NON-INFRINGEMENT AND IMPLIED WARRANTIES
ARISING FROM COURSE OF DEALING OR COURSE OF PERFORMANCE. 

 

9.LIMITATION
OF LIABILITY. 

 

	 	A.	Exclusion of Damages . [*******]

 

	 	B.	Argus Not An Insurer Or Healthcare Provider. [*******]

 

	 	C.	Excluded Liabilities. [*******]

 

	 	D.	Liability Limitation. [*******]

 

10.INDEMNITY. 

 

A.General
Indemnification Provisions. Subject to Section 9 (Limitation of Liability) of this MSA, each party shall indemnify and
defend the other party and their shareholders, officers, directors, employees, affiliates and agents, and the successors, representatives
and assigns thereof (the “Indemnified Parties”) for, and hold them harmless from and against, any and all liability,
loss, damage and expense, including reasonable attorneys fees, arising directly or indirectly from third-party claims against
the other party (the “Losses”) that are the direct result of such party’s material breach of this MSA. In addition,
Customer shall indemnify and defend the Argus Indemnified Parties for, and hold them harmless from and against, any and all Losses
of Argus relating to the contents or coverage of a Program or to actions or inactions by Argus in compliance with Customer instructions,
except to the extent that such Losses are the direct result of Argus' material breach of this MSA.

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 5

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

 

B.Indemnity Procedures.
Each party’s obligation to indemnify shall apply only if the party to be indemnified has given the party providing the indemnity
(“Indemnifying Party”) prompt written notice of the claim, provides all reasonable information and assistance to the
Indemnifying Party for the Indemnifying Party to settle or defend the action, and grants the Indemnifying Party the sole authority
to control the defense and settlement of the claim. 

 

11.TERMINATION.

 

A.Termination
for Material Breach. If there is any material default by either party in the performance
of the terms and conditions of this MSA, the non-defaulting party may terminate this MSA upon sixty (60) days’ prior written
notice; provided, however, that the defaulting party has not cured such default within ten (10) days prior to the end of such
sixty (60) day period. If either party defaults under this MSA, the other party will use commercially reasonable efforts to mitigate
damages caused by such default. 

 

B.Obligations Upon Termination.
Upon expiration or termination of this MSA: (a) Customer will pay contemporaneously with the expiration or termination date all
amounts due Argus; (b) Customer will timely pay all subsequent invoices (1) for services performed and expenses incurred on
or prior to the expiration or termination date, and (2) for expenses associated with the return to Customer at Customer’s
request of (i) on-line data transferred to electronic media at Argus’ discretion and archived media stored by Argus, and
(ii) direct Member reimbursement and other paper Claim forms; (c) Argus will deliver to Customer within forty-five (45) business
days of the expiration or termination date the balance of any funds delivered by Customer to Argus for the payment of Claims Processed
on Customer’s behalf through IPNS, less all sums outstanding which are owed by Customer to Argus; and (d) unless Customer
and Argus otherwise agree pursuant to a post-processing agreement, Argus shall not be required to continue to perform services
hereunder, including without limitation making adjustments to transactions or providing ongoing storage and maintenance of records.

 

C. Termination for Insolvency/Bankruptcy.
Either party may terminate this MSA effective immediately without liability upon written notice to the other if any one of the
following events occurs: (i) the other files a voluntary petition in bankruptcy or an involuntary petition is filed against it,
(ii) the other is adjudged as bankrupt, (iii) a court assumes jurisdiction of the assets of the other under federal reorganization
act, (iv) a trustee or receiver is appointed by a court for all or a substantial portion of the assets of the other, (v) the other
becomes insolvent, or (vi) the other makes an assignment of its assets for the benefit of its creditors.

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 6

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

 

12. CONFIDENTIALITY.

 

A. Privacy Regulations.
The parties are subject to the obligations set forth in the Privacy/Security Regulatory Addendum attached hereto.

 

B. Proprietary Information.

 

1.
General. Proprietary Information shall include the following: (a) the terms of this MSA (but not the existence thereof)
and all information disclosed by each party to the other pursuant to this MSA; (b) any information or material that would give
a third party some competitive business advantage or the opportunity of obtaining such advantage, or the disclosure of which could
be detrimental to the interests of a party to this MSA including, but not limited to, a party’s databases, software, systems,
products, services, layouts, designs, formats, procedures in any form of expression, processes, tags, applications, interfaces,
interface formats, technology and all elements thereof, files, compilations, analyses, publications, edits, protocols, documents,
reports, and any derivative works (as defined in the Copyright Act of 1976, as amended), developments,
changes, modifications or new features relating thereto; (c) any information or material which is marked “Confidential,”
“Restricted,” or “Proprietary Information” or other similar marking; (d) any information or material
known by the parties to be considered confidential or proprietary; or (e) any information or material which should be known
or understood to be confidential or proprietary by an individual exercising reasonable commercial judgment in the circumstances.
Each party acknowledges and agrees that the other party’s Proprietary Information constitutes confidential material and
trade secrets of the other party.

 

2. Exclusions. The term
“Proprietary Information” does not include information which (a) has been or may in the future be published or is now
or may in the future be otherwise in the public domain through no fault of the receiving party; (b) prior to disclosure pursuant
to this MSA, or during negotiations therefore, is property within the legitimate possession of the receiving party; (c) subsequent
to disclosure pursuant to this MSA is lawfully received from a third party having rights in the information without restriction
of the third party’s right to disseminate the information and without notice of any restriction against its further disclosure;
(d) is independently developed by the receiving party through its agents who have not had access to such Proprietary Information;
or (e) is obligated to be produced under order of a court of competent jurisdiction or other similar requirement of a governmental
agency.

 

C.
Use of Proprietary Information. Customer acknowledges and agrees that from time to time: (1) Argus uses certain information
which is not identifiable by Member or Argus customer to report industry trends, benchmarks and the like (“Blind Reporting”),
(2) Argus may provide Member or other Customer information to state or federal bodies (or their parties acting on behalf of such
bodies) that request it for Medicaid or Medicare subrogation or for other purposes the agencies represent is allowed by law (“Required
Reporting”), and (3) Argus discloses Customer Proprietary Information to Contracted Pharmacies as Argus deems necessary
to operate the Argus Network or Customer Network. Each party agrees to hold the other party’s Proprietary Information in
confidence, to use and reproduce such Proprietary Information only to accomplish the intent of this MSA, and to use reasonable
care to avoid unauthorized disclosure or use of the Proprietary Information; provided, however, that Argus may use Customer’s
Proprietary Information as set forth herein.

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 7

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

 

D. Right to
Disclose. Each party represents and warrants that it has the right to disclose its Proprietary Information to the other party.

 

E. Return or
Destruction of Proprietary Information. The parties agree that immediately upon termination, cancellation, expiration or other
conclusion of this MSA, without regard to the reason for termination, the parties shall return to one another or destroy, in the
disclosing party’s sole discretion, all materials containing Proprietary Information that is the property of the other party.
The parties will complete such return or destruction as promptly as possible, but in no event later than thirty (30) days after
the effective date of the termination, cancellation, expiration or other conclusion of this MSA. Within such thirty (30) day period,
each party will certify in writing to the other party that such return or destruction has been completed.

 

F. Governmental Disclosures.
If a party is required to file this MSA or any portion thereof with, or to provide any information pertaining to this MSA to, any
state or federal agency or regulatory body, it shall notify the other party sufficiently in advance for the parties to work together
to redact such provisions and to keep confidential such information as the other party deems sensitive. Customer acknowledges that
at a minimum Argus considers all monetary provisions, damage limitation and formulas in this Agreement as confidential, as well
as any Argus Network disbursement schedules and other monetary amounts contained in any portion of this MSA or in an election form.
Each party shall use its best efforts to advance the position of the other party with the governmental agency or regulatory body
that such provisions or information should not be provided or should not be made publicly available, and each party shall keep
the other party apprised of any decision by the agency or regulatory body in this regard. Each party shall provide the other party
with copies of all written communications with the agency or regulatory body pertaining to the services to be provided hereunder
or to this MSA.

 

G. Press Releases. Neither
party shall release information to the press or, except as necessary to perform its obligations hereunder, over the Internet referring
to the terms and provisions of this MSA without the express written consent of the other party. Nothing herein shall prevent a
party from disclosing the mere existence of this MSA.

 

13.OWNERSHIP.
All Proprietary Information, unless otherwise agreed in writing, remains the exclusive property of the disclosing party. Each
party shall retain full and exclusive ownership and all rights over its respective Proprietary Information, and the programming,
conception, development or enhancement thereof, and over its publications, trade secrets, copyrights, trademarks and patents,
and the other party shall not purport to have ownership thereof. Customer shall not copy, reverse engineer, decompile or disassemble
or otherwise attempt to create or derive the source code of any Argus software or system. Customer agrees not to take any action
which would mask, delete or otherwise alter any Argus on-screen disclaimers or copyright, trademark and service notifications
provided by Argus from time to time, or any “point and click” features relating to acknowledgement and acceptance
of such disclaimers and notifications.

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 8

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

 

14.
AUDITS/SUBPOENAS.

 

A. Customer Audits of Argus
Services. Customer may, at its cost and expense, conduct audits of the records and information pertaining to services Argus
provides to Customer that are reasonable in scope and conducted at reasonable times during the regular business hours of Argus.
Customer hereby agrees that any Customer-designated auditors must not have a conflict of interest with Argus or its affiliates
or sub-contractors and shall be subject to confidentiality provisions equal to or more stringent than required of Customer under
this MSA. Any audit performed under this MSA shall (i) be coordinated through the internal controls function or office of Argus
or its subcontractors, (ii) be reasonably designed not to interfere with Argus’ operations or the operations of its subcontractors,
the uptime, stability or efficiency of such operations or the standard security requirements of the applicable entity, (iii) not
violate any laws, regulations or orders applicable to Argus or its subcontractors, (iv) not cause Argus to breach any contractual
obligation, (v) be limited to the systems, controls, processes, records and details specifically applicable to the provision of
services for Customer hereunder, and (vi) not cause access to any data not related to or arising from the performance of services
for the Program. Audit requests will be in writing and given not less than thirty (30) days prior to the anticipated date of the
audit. After expiration or termination of this MSA, Customer may only request an audit of Argus’ records, including those
of its subcontractors, if such audit is for regulatory purposes and such audit is exclusively conducted by a governmental agency,
or as otherwise required by law.

 

B. Audits of Customer Data.
Argus shall allow regulators and third parties to whom Customer has given audit rights to audit services provided hereunder as
required by regulations applicable to Customer, and Customer shall give Argus prompt written notice upon learning that any such
regulatory audit is to occur. Customer shall fully reimburse Argus for its costs and expenses in any such regulatory audit.

 

C.SSAE 16 Audit. On
an annual basis, Argus shall provide Customer with a SSAE 16 audit report, performed in accordance with the American Institute
of Certified Public Accountants Statement on Standards for Attestation Engagements No. 16, Reporting on Controls at a Service Organizations
(the “SSAE 16"). The SSAE 16 will cover claims processing performed by Argus on behalf of Customer.

 

D.Reimbursement of Expenses.
Because Argus has costs associated with the retrieval of archived data and is keeping data on Customer’s behalf, Customer
shall reimburse Argus for the expenses and attorney’s fees Argus incurs in responding to subpoenas, garnishments, or other
legal processes involving requests for Customer information or property, provided that (except for instructions to redirect Disbursements
from one Contracted Pharmacy to another due to an assignment of assets, bankruptcy or other transaction) Argus has notified Customer
of the request prior to complying. 

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 9

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

 

15.FORCE MAJEURE. Any party’s
delay in, or failure of, performance under this MSA shall be excused where such delay or failure is caused by the following: (a)
an act of nature, fire, act of war, terrorist act, pandemic or other catastrophe; (b) electrical, computer, software, transmission,
power, communications or mechanical failure; (c) work stoppage, delays or failure to act of any carrier or agent; (d) direction
or effect of an order from a court or government agency or body; (e) functions or malfunctions of the Internet, telecommunications
services (including wireless), firewalls, encryption systems or security devices; or (e) any other cause beyond a party’s
reasonable control. In the event such acts result in a delay by Customer of payment of sufficient funds to the appropriate Argus
disbursing account, Argus shall not be required to disburse any funds to the respective Contracted Pharmacies unless and until
such payment is made by Customer as provided in Exhibit D (Claims Processing and Related Services).

 

16.COMPLIANCE WITH LAWS. 

 

A. Regulation
of Argus Services. Argus represents and warrants that it will take reasonable steps to comply with the laws, regulations, and
governmental policies, guidelines and instructions applicable to its provision of services under this MSA (“Governmental
Obligations”), provided that Customer complies with its obligations and has satisfied the representations and warranties
in this Section. Customer represents and warrants that the obligations referred to in the Service Exhibits set forth all of Argus’
performance obligations, including without limitation formats for data transmission and time periods for Disbursements, required
by such Governmental Obligations on the Effective Date.

 

B. Customer
Notice to Argus of Regulated Changes to Services. Customer agrees to promptly notify Argus of any Governmental Obligations
(regardless of whether they existed on the Effective Date) that impact or add to such specific performance obligations hereunder
(“Additional Obligations”) as soon as practical after Customer has become aware of the same, including without limitation
any changes to the specific performance obligations required by any regulatory addendum the parties may attach hereto.

 

C.Addressing Additional Regulatory
Obligations. If Argus is notified in writing by Customer or otherwise that Argus’ performance obligations require a formal
amendment of the Service Exhibits, Argus shall make such changes as the structure of IPNS allows at Argus’ then current
rates or as mutually agreed to by Customer and Argus. Argus, within ten (10) business days of such notice,
may provide Customer with its written objection to performing the Additional Obligations, and may request consultation with Customer.
Not later than ten (10) days after the date of such objection, the parties shall discuss in good faith the possibility of a mutually
satisfactory resolution of the issue; provided, however, that in the event the parties fail to reach written agreement on a mutually
satisfactory resolution within forty-five (45) days after the date of the objection, Argus, if
it believes in good faith that the proposed alteration will have a materially adverse financial effect on its interests in this
MSA, shall have a right to immediately terminate this MSA by providing written notice to Customer. Customer shall not assert
any claim against Argus for monetary damages or equitable relief or otherwise for Argus’ failure to perform the Additional
Obligation from the date of notice to Argus of the Additional Obligation through the date agreed to by the parties for implementation
of such obligation, or, if Argus exercises a right to terminate the Agreement, through the termination date.

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 10

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

 

D. Customer Compliance.
Customer agrees to comply with all (a) laws, regulations, and governmental policies, guidelines and instructions applicable to
receipt from Argus of services hereunder, and (b) legal, contractual or other obligations that it has with its Members; provided
however, that a breach of this obligation shall not relieve Customer of its obligations in this Section or elsewhere in this MSA.

 

17.MISCELLANEOUS
LEGAL PROVISIONS.

 

A.Notices. Notices
under this MSA shall be given in writing by personal delivery, prepaid certified or registered mail return receipt requested, independent
overnight courier, or facsimile transmission with a copy sent by certified mail, registered mail, or independent overnight carrier
to follow addressed as follows (or at such other address as shall be given by either of the parties to the other pursuant to this
Section):

 

	Argus:	 	HCA -PCA
	Argus Health Systems, Inc.	 	Healthcare Corporation of America -
	[*******]

	 	Prescription Corporation of America, Inc.
	 	 	66 Ford Road, Suite 230
	 	 	Denville, New Jersey 07843
	 	 	Facsimile: 973-983-6304

 

B.Assignment.
This MSA and the rights and obligations hereunder shall not be assigned by either party without prior written consent of the
other party; provided, however, that such consent shall not be required in the event this MSA, or any rights or obligations hereunder,
are assigned by a party as a result of the sale of substantially all of the party’s business or assets or as a result of
a reorganization, merger or business consolidation involving the assigning party. This MSA shall be binding upon and inure to
the benefit of the respective successors, permitted assigns and legal representatives of the parties hereto.

 

C.Counterparts. This MSA
may be executed in counterparts, all of which together shall be deemed one and the same agreement.

 

D.Governing Law.  This MSA
shall be governed by and construed in accordance with the laws of the State of Missouri without regard to its principles of conflicts
of law.

 

E.Independent Contractor.
Customer and Argus shall be considered independent of each other at all times. Nothing in this MSA shall be construed to constitute
the existence of any agency, joint venture, partnership or fiduciary relationship between the parties. Argus shall choose the means
to be employed and the manner of carrying out its obligations in this MSA.

 

F.Entire Agreement. This
MSA, together with the exhibits and addenda hereto, constitutes the entire understanding of the parties with respect to the subject
matter of this MSA and supersedes and replaces all prior or contemporaneous responses to requests for proposals or information,
marketing literature, negotiations, understandings and representations, whether oral or written. No supplement, modification or
amendment of this MSA shall be binding unless contained in a writing signed by each of the parties to this MSA. No agent of any
party hereto is authorized to make any representation, promise or warranty inconsistent with the terms hereof.

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 11

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

G.Validity. If an arbitrator,
court or administrative agency determines any provision of this MSA invalid, the provision shall be interpreted to the greatest
extent permitted by law to give effect to the parties’ intentions, and the determination shall not affect the enforceability
of any other provision.

 

H.Waiver. The waiver by
any party of any breach of any provisions of this MSA shall not operate, or be construed, as a waiver of any subsequent breach.

 

I.No Third-Party Beneficiaries.
This MSA is intended solely for the benefit of the parties. In no event will any third party, including without limitation any
Program Sponsor, Pharmacy, Prescriber, Member, bank, governmental entity, or contractor or client of Customer, have any rights
under or right to enforce the terms of this MSA.

 

J.Binding Effect. This MSA
shall be binding upon each party’s successors and permitted assigns and shall inure to the benefit of and be enforceable
by each party’s successors and permitted assigns.

 

K.Equitable Relief. The
parties agree that monetary damages will be difficult to ascertain in the event of any breach of Section 12 (Confidentiality)
or of Section 13 (Ownership) and that monetary damages alone would not suffice to compensate a party for such breach. The parties
agree that in the event of any violation of Section 12 (Confidentiality) or Section 13 (Ownership) of this MSA, without limiting
any other rights and remedies, an injunction may be brought against any party who has breached or threatened to breach these provisions,
without the requirement to post bond. In any proceeding upon a motion for equitable relief, a party’s ability to answer as
to damages shall not be interposed as a defense to the granting of such equitable relief.

 

L.Survival. Termination
of this MSA for any reason shall not terminate any limitation of liability or indemnification provisions or release either party
from any liability which at the time of termination has already accrued to the other party or which thereafter may accrue with
respect to any act or omission occurring prior to termination; provided, however, that Argus’ obligation in Section 8B (Re-Performance
Obligations) to re-perform shall not survive for longer than six (6) months after termination or expiration of the MSA.

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 12

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

 

M.Headings. The headings
in this MSA are for convenience only and shall not be used to construe the meaning of the provisions in or to interpret this MSA.

 

N.Other Business.
Argus may participate in claim verification programs involving certain public benefits (i.e., governmental relief programs), health
plans, pharmaceutical manufacturers and other parties that are utilized to facilitate instant rebates, coupons or instant savings
at the point of sale. Argus will not sponsor these programs and will only provide its traditional back office infrastructure and
administrative services (claims processing, retail network and reporting) to support these programs. Argus will process these claims
for secondary funding eligibility and available secondary funding may be credited to the patient electronically at the point of
sale and applied to amounts not covered by the primary payor, including co-payments. Authorized pharmacy reimbursements may be
funded by the applicable party that contracts with Argus for these services. The claim verification programs will not involve Member
data or information on the primary payor, even if such payor is an Argus client, and Argus will be unable to verify formulary status
of submitted secondary claims.

 

 

[Signatures on the following page]

 

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 13

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

 

The parties have caused this MSA to
be executed by their respective duly authorized officers or agents as of the date set forth below.

 

 

	ARGUS HEALTH SYSTEMS, INC.	HEALTHCARE CORPORATION OF 

AMERICA – PRESCRIPTION 

CORPORATION
        OF AMERICA, INC
	 	 
	 	 
	
        

        By:/s/ Patricia Yakimo

         

        Printed Name: Patricia Yakimo

         

        Title: Senior Vice President
        

         

        Date: 11-18-11
	
        

        

        By:/s/ Ann F. Saskowitz

         

        Printed Name: Ann F. Saskowitz

         

        Title:Vice President Service Operations

         

        Date: 11-18-11

         

 

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 14

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

EXHIBIT A: DEFINITIONS

 

access
information means the unique identifier, password and related information necessary for Customer’s on-line
users to have the electronic capability to view and modify IPNS files or to use RxFocus®.

 

ARGUS FORMAT means with respect
to Claims submitted or Claims history provided on electronic or magnetic media, the NCPDP or other industry standard format specified
or accepted and machine readable by Argus and containing Required Information. With respect to Claims submitted or Claims history
provided on paper, a UCF Form and Argus transmittal form containing legible, complete and identifiable information and forwarded
to an Argus-designated post office box. With respect to IPNS® file information, complete, legible, and identifiable information
in the record layout specified or approved by Argus.

 

Argus
Network means a group of Argus Pharmacies that have agreed to participate in an Argus Network under a Participating
Pharmacy agreement.

 

Argus
Network Agreement (ANA) means the applicable Disbursement schedule elected by an Argus Pharmacy by executing
an Argus Network Election.

 

ARGUS
PHARMACY or ARGUS PharMACIES means a Pharmacy that has elected,
either independently or through an Intermediary, to participate in an Argus Network which Customer is utilizing.

 

CHECK REGISTER means for a Financial
Cycle, a listing of checks to be issued to Participating Pharmacies in Customer Networks.

 

CLAIM is the request of a Contracted
Pharmacy or a Member for amounts due under a Program to the Contracted Pharmacy or Member subsequent to the Contracted Pharmacy’s
provision of prescription drugs or of certain other healthcare-related products or services to a Member.

 

CONTRACTED PHARMACY or PHARMACIES
means all Argus Pharmacies and Participating Pharmacies.

 

Copayment
means that portion of a Contracted Pharmacy charge that a Member is required to pay the Contracted Pharmacy in accordance with
the applicable Program.

 

Covered
Medications means those prescription drugs, injectables, compounds, supplies, and other items which are legally prescribed
by an authorized, licensed Prescriber and are covered by a Program.

 

CUSTOMER
Network means a group of Participating Pharmacies that have agreed to participate in a Network under an agreement with
Customer.

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 15

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

 

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

DISBURSEMENT means an amount due
a Contracted Pharmacy under a Participating Pharmacy agreement and paid to the Contracted Pharmacy after a Financial Cycle pursuant
to the terms of Exhibit D (Claims Processing and Related Services).

 

DISPENSE AS WRITTEN (DAW) CODE is
the code promulgated by the NCPDP used to indicate the reason for dispensing a multi-source brand-named medication.

 

DRUG UTILIZATION REVIEW (DUR) MESSAGE
means an on-line message that alerts a Contracted Pharmacy of a potential interaction and/or potential resulting therapeutic implications
of various drugs.

 

ELIGIBLE means a Member is entitled
to Pharmacy Services under a Program.

 

FINANCIAL CYCLE(S) is the interval
of time between payment by Customer, Argus or others to Pharmacies or Members of amounts due under a Program.

 

Identification
CarD means a printed card that is issued by Argus or Customer to a Member and that is used to identify the Member and
covered dependents (but not to guarantee Program coverage of a particular Pharmacy Service).

 

INTEGRATED PHARMACY NETWORK SYSTEM (“IPNS®”)
is Argus’ system for the electronic processing of prescription and certain other Claims submitted under Programs.

 

INTERMEDIARY means a pharmacy services
administrative organization or an owner or operator of a Contracted Pharmacy.

 

INTERNET
means an interconnected system of networks that connects computers around the world.

 

Maximum
Allowable Cost (MAC) means the maximum allowable cost of a drug pursuant to a list that establishes an upper
limit reimbursement price for certain multiple-source drugs dispensed without regard to the specific manufacturer whose drug is
dispensed.

 

MEMBER is a person who is enrolled
in the Program, meets all of the eligibility requirements for membership in such Program and is entitled to the healthcare-related
benefits of the Program.

 

NATIONAL COUNCIL FOR PRESCRIPTION DRUG
PROGRAMS (NCPDP) is a pharmaceutical-industry trade association that has developed a format used for the transmission between
Pharmacies and claims processors on electronic or magnetic media of pharmacy Claim data and issues NPI numbers.

 

NATIONAL DRUG CODE (NDC) is an identifier
for a prescription drug published by the pharmaceutical industry.

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 16

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

NaTIONAL
PROVIDER IDENTIFIER (NPI) is a unique identification number issued by NCPDP for use by covered health care providers
to identify Prescribers as required by the Health Insurance Portability and Accountability Act (HIPAA) Administrative Simplification
Standard.

 

NaTIONAL
WRAP NETWORK means a group of Argus Pharmacies that have agreed to receive Disbursements at rates set forth in the applicable
ANA.

 

Network
means a group of Contracted Pharmacies that have agreed to participate in an Argus Network or a Customer Network.

 

PAID CLAIM is a Claim that has been
found to represent a covered healthcare-related benefit and requires reimbursement by the Plan, or Member.

 

PARTICIPATING PHARMACY is any person
or entity properly licensed to dispense prescription drugs which has a written agreement with Customer, or its network pharmacy
administrator, to provide Products and services to Members.

 

PAYMENT REGISTER means for a Financial
Cycle, a listing of payments due each pharmacy participating in an Argus Network resulting from Argus’ Processing Claims
on behalf of Customer.  

 

PHARMA COMPANY is a pharmaceutical
company.

 

PHARMACY(IES)
shall mean shall mean any outlet engaged in the business of dispensing, compounding or selling
Products to patients or consumers.

 

PHARMACY
Laws means all local, state and federal laws, regulations, constitutions, charters, acts, statutes, ordinances, codes,
rules, orders, decrees, judgments, or other legislative, judicial, or administrative actions applicable to Contracted Pharmacies.

 

Pharmacy
Services means those pharmacy services provided through a Network, including the dispensing of Covered Medications and
related counseling and Product consultation.

 

Pharmacy
Standards means standards that meet the greater of (a) the pharmaceutical care, skill and diligence that is customarily
rendered by pharmacies in the United States (if measurable, or if not measurable, that is customarily rendered in the largest geographical
area for which it is measurable), or (b) the pharmaceutical care, skill and diligence that is customarily rendered by Contracted
Pharmacies as a group.

 

PRESCRIBER is a physician or other
healthcare professional who legally prescribes a healthcare-related product or service to Members and such person’s agents
and has obtained an NPI number from NCPDP.

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 17

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

PROCESS(ING) is the review of Claims
to determine whether and to what extent they meet Program Specifications, and, if Customer requests, the determination of amounts
due a Pharmacy or, if applicable, a Member under a Program.

 

Processing
Messages are messages sent electronically by Argus pertaining to Network or Program information, including without limitation
step therapy protocol and formulary information.

 

PRODUCT is any pharmaceutical product
of a Pharma Company.

 

PROGRAM is the contractual provision
by an entity other than Argus of healthcare benefits to Members pursuant to which the Pharmacies and, if applicable, Members, receive
funds for prescription drugs, durable medical equipment, and other healthcare-related goods and services as determined by a unique
combination of factors including without limitation coverage specifications, reimbursement criteria and methods, and eligibility
requirements.

 

PROGRAM SPECIFICATIONS is the IPNS
specifications agreed to by Customer and Argus that reflect the combination of Program and healthcare industry factors that determine
amount due to Pharmacies and, if applicable, Members, under a Program.

 

PROGRAM SPONSOR is the entity that
contracts for the provision of healthcare benefits to Members.

 

REQUIRED INFORMATION means complete,
identifiable (and if submitted on paper, legible) Claim information required by Argus. Required Information may include without
limitation (a) Member’s identification number; (b) NDC of the medication prescribed; (c) the bottle size from which the medication
is dispensed; (d) quantity of the medication dispensed; (e) estimated days of medication supply; (f) the correct DAW code for brand
name medications; (g) an NPI number; (h) codes and cost information as designated by Argus for compound prescriptions; and (i)
sales tax amounts.

 

Sales
Tax Remittances are amounts Argus (a) has based on information obtained from Participating Pharmacies regarding any
federal, state or local taxes payable with respect to any sales of Covered Medications to Members and determined to be reasonable,
(b) has collected from Customer, and (c) has remitted with Disbursements to Participating Pharmacies.

 

SUBMITTED CLAIM means any Claim
type that is identified as submitted on behalf of the Customer and requires processing by Argus.

 

UNIVERSAL CLAIMS FORM (UCF) is a
form developed by NCPDP that is the accepted format for non-electronic submission of Claims for reimbursement to a Pharmacy to
a Claims processor.

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 18

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

UNIVERSAL PRODUCT CODE (UPC) is
a manufacturer’s unique, universally recognizable code for a Product.

 

USUAL AND CUSTOMARY CHARGE means
the lowest price the Contracted Pharmacy would charge to a cash paying customer for an identical prescription on the date and at
the location that the prescription is dispensed, including any special promotions or discounts available to the public on such
date of dispensing.

 

WHOLESALE ACQUISITION COST (WAC)
means a Pharma Company’s wholesale price for a drug provided by a Pharma Company to third-party pricing sources (e.g., First
DataBank) for inclusion in their price databases.

 

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 19

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

EXHIBIT B: LIABILITY LIMIT CALCULATION

 

[*******]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 20

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

EXHIBIT C: FEES AND EXPENSES

 

 

 

 

 

[*******]

 

 

 

 

 

 

 

 

 

 

 

 

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 21

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED.

INFORMATION FOR WHICH CONFIDENTIAL TREATMENT
HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]”
OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION
OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND
EXCHANGE COMMISSION.

 

 

EXHIBIT D:

CLAIMS PROCESSING AND RELATED SERVICES

[*******]

 

 

 

 

 

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 22

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

 

    	 

    	 

    

 

 

EXHIBIT E:

PHARMACY NETWORK SERVICES

[*******]

 

 

 

 

 

 

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 23

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

 

    	 

    	 

    

 

 

EXHIBIT F:

TARGETED INTERVENTION STRATEGIESTM

[*******]

 

 

 

 

 

 

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 24

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

 

    	 

    	 

    

 

 

EXHIBIT G

PAHUB AUTOMATED AUTHORIZATION SERVICES

[*******]

 

 

 

 

 

 

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 25

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

 

    	 

    	 

    

 

 

EXHIBIT H

PREDICTIVE MODELING

DSTHS ACG®END USER RxPMTm ONLY PRODUCTION LICENSE

[*******]

 

 

 

 

 

 

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 26

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

 

    	 

    	 

    

 

APPENDIX 1

PHARMACY NETWORK SERVICES ARGUS

NETWORK ELECTIONS

(Form)

[*******]

 

 

 

 

 

 

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 27

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.

 

    	 

    	 

    

 

 

PRIVACY/SECURITY REGULATORY ADDENDUM

[*******]

 

 

 

 

 

 

 

Management
Services Agreement

Healthcare
Corporation of America – Prescription Corporation of America, Inc.

Page 28

 

Copyright
2011 by Argus Health Systems, Inc. All Rights Reserved All of the information on this page constitutes a trade secret, privileged
or confidential information, as such terms are interpreted under the Freedom of Information Act and applicable case law.This restated EMPLOYMENT
AGREEMENT (the “Agreement”) is dated as of 8th day of May, 2013 by and between Selway Capital Acquisition
Corporation, a Delaware corporation, and its wholly owned subsidiaries, Healthcare Corporation of America, Prescription Corporation
of America, and Prescription Benefits, Inc., each being a New Jersey corporation with offices located at 66 Ford Road, Suite 230,
Denville, New Jersey 07834 (hereinafter collectively referred to as the “Employer” and/or the “Company”),
and Yoram Bibring, an individual residing at 421 Lewelen Circle, Englewood, New Jersey 07631 (the “Executive”).

 

WHEREAS, the Employer
desires to obtain the services of and employ the Executive, and the Executive desires to provide such services and continue such
employment, each on the terms and conditions hereinafter set forth.

 

NOW THEREFORE,
in consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.Employment;
Term; Title; Authority.

 

(a)Employment.
The Employer hereby employs the Executive, and the Executive hereby accepts employment with the Employer, upon the terms set forth
in this Agreement.

 

(b) Term. Executive’s
employment shall commence as of June 3, 2013 and continue for a period of thirty-six (36) months thereafter unless such employment
is otherwise terminated pursuant to Section 6 of this Agreement (such period of employment, the “Term”).

 

(c) Position &
Duties. The Executive shall serve as the Chief Financial Officer of the Employer during the Term and shall be subject to the
supervision of, and shall report to the Chairman and Chief Executive Officer of the Company (“CEO”) and shall be further
subject to the supervision of the Audit Committee of the Board of Directors of the Company when such committee is formed by the
Company. The Executive’s responsibilities will include all financial and accounting activities and periodic reporting, attendance
at Board meetings, investor relations, coordination with SEC counsel, analysis and evaluation of merger and acquisition activities
and large transactions. Without the prior approval of the CEO, the Executive shall not take or authorize to be taken any action
(a) outside the ordinary course of the Employer’s business, (b) that involves a material long-term commitment of the Employer
or (c) that contravenes any policies, procedures or directives (i) adopted by the Board or (ii) communicated to the Executive by
any member of the Executive Committee of the Board other than the Executive.

 

2. Extent of Services.

 

(a)Extent
of Services. The Executive agrees to devote the Executive’s full business time and attention, except during any period
of illness, incapacity or vacation, to the performance of the Executive’s duties under this Agreement. The Executive shall
perform such duties to the best of the Executive’s ability and shall use reasonable best efforts to further the interests
of the Employer. Subject to the approval of the CEO, the Executive shall have the right to engage in other business activities
which do not conflict with or impair the performance of any of the Executive’s duties hereunder; provided, however,
that nothing in this Section 2(a) shall be deemed to prohibit the Executive from serving on corporate, industry, civic,
or charitable boards or committees or participating in such other charitable, educational, religious, civic or similar activities
in any manner, so long as such activities do not inhibit, conflict or interfere with the discharge of the Executive's duties hereunder.
The Executive shall perform the Executive’s assigned duties diligently, loyally, conscientiously and with reasonable skill
and shall comply in all material respects with all of the Employer’s rules, procedures and standards applicable from time
to time to employees of the Employer with respect to the Executive’s conduct and access to and use of the Employer’s
property, equipment and facilities.

 

    	-1-

    	 

    

 

(b) Place of Performance.
The Executive will perform his services principally in the Denville, New Jersey office of the Employer (“Place of Performance”).
The Executive acknowledges that his position may include some travel responsibilities.

 

(c) No Conflicts.
The Executive represents and warrants to the Employer as of the date of this Agreement that: (i) the Executive is able to enter
into this Agreement and that the Executive’s ability to enter into this Agreement and to fully perform all duties hereunder
are not limited to or restricted by any agreements or understandings between the Executive and any other Person; and (ii) other
than employee benefits generally available to employees of the Employer, this Agreement is the only agreement (written, verbal
or otherwise), transaction, arrangement or other commitment of any kind between the Executive and the Employer (or any Affiliate
of the Employer) under which the Executive is or may become entitled to receive payment, fringe benefits or other financial benefits.

 

(d) Definitions.
For the purposes of this Agreement: (i) "Affiliate" means, with respect to any Person, any Person directly or
indirectly controlling, controlled by, or under common control with such Person. For purposes of this definition, the terms "controlling",
"controlled by", or "under common control with" shall mean the possession, direct or indirect, of the power
to direct or cause the direction of 10% or more of the management and policies of a Person, whether through the ownership of voting
securities, by contract, or otherwise; (ii) "Family Member" means, with respect to any Person, any child, stepchild,
grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law,
or sister-in-law (including adoptive relationships) of such Person; and (iii) “Person” means any natural person,
corporation, partnership, limited liability partnership, limited liability company, or any other entity of any nature, including
any unincorporated association.

 

    	-2-

    	 

    

 

3. Compensation

 

(a) Base Salary.
During the Term, the Employer shall pay the Executive an annual base salary of $250,000.00 payable in accordance with the Employer’s
customary payroll procedures (the “Base Salary”). The Base Salary shall be reviewed on an annual basis by the
CEO. All compensation payable to the Executive from the Employer or its affiliates shall be subject to all applicable withholding
taxes, normal payroll withholding and any other amounts required by law or the terms of any applicable benefit plan or program
to be withheld.

 

(b) Bonus Program.
The Executive shall be eligible for a $100,000 annual bonus on a fiscal year basis subject to all terms and conditions of Employer’s
then current bonus plan for senior management. Fifty percent (50%) of the Executive’s annual bonus compensation may, at the
discretion of the Company, be paid each year in registered shares of the Company’s common stock.

 

(c) Stock Options.
Subject to implementation of a fully approved and legally compliant employee stock compensation program, the Executive shall be
issued 200,000 stock options at an exercise price equal to the fair market value per share as of the date of grant. These options
will vest over a three year period in monthly increments beginning November 1, 2013. These options will vest immediately upon a
Change of Control of the Company which shall mean the sale or transfer of all or substantially all of the assets of the Company
or the sale of more than fifty percent (50%) of the shares of capital stock of the Company entitled to vote generally for the election
of directors of the Company.

 

(d) Sign-On Bonus:
Upon execution, the Company shall pay the Executive a one-time bonus in the sum of $18,500.

 

4. Employee Benefits.

 

(a) Fringe Benefits.
The Employer shall afford the Executive the opportunity to participate in any health care, dental, disability insurance, retirement,
savings and any other employee benefits plans, policies or arrangements which the Employer maintains for its senior executives,
including the CEO, in accordance with the written terms of such plans, policies or arrangements. Nothing in this Agreement shall
require the Employer to establish, maintain or continue any benefit plans, policies or arrangements or restrict the right of the
Employer to amend, modify or terminate any such benefit plan, policy or arrangement.

 

(b) Holidays, Vacation.
The Executive shall be entitled to all public holidays observed by the Company and four weeks’ vacation in his first and
all subsequent years of service. The Executive shall take vacation at a reasonable time or times.

 

5.Reimbursement
of Business Expenses.

 

The Employer shall reimburse
the Executive in accordance with Employer’s reimbursement policies for all reasonable out-of-pocket costs incurred or paid
by the Executive in connection with, or related to, the performance of the Executive’s duties, responsibilities or services
under this Agreement.

 

    	-3-

    	 

    

 

6.
Termination; Severance.

 

(a)Definition
of Cause. The Executive's employment hereunder may be terminated by the Employer at any time with or without Cause.
For purposes of this Agreement, the term “Cause”
shall mean any of the following: (A) your neglect or willful failure or refusal to perform your duties hereunder (other than as
a result of total or partial incapacity due to physical or mental illness); (B) engaging in gross misconduct; (C) perpetration
of an intentional and knowing fraud against or affecting the Company or any of its affiliates or any customer, agent, or employee
thereof; (D) any willful or intentional act that could reasonably be expected to injure the reputation, business, or business relationships
of the Company or any of its affiliates or Executive’s reputation or business relationships; (E) your material failure to
comply with, and/or a material violation by you of, the internal policies of the Company or any of its affiliates and/or procedures
or any laws or regulations applicable to your conduct as an employee of the Company; (F) conviction (including conviction on a
nolo contendere plea) of a felony or any crime involving fraud, dishonesty or moral turpitude.

 

For purposes of this
Section 6, no act or failure to act, on the part of the Executive, shall be considered “willful” unless it is
done, or omitted to be done, by the Executive in bad faith or without reasonable belief that the Executive's action or omission
was in the best interests of the Employer. Any act, or failure to act, based upon authority given pursuant to a resolution duly
adopted by the Board or upon the instructions of the Chairman of the Board or based upon the advice of counsel for the Employer
shall be conclusively presumed to be done, or omitted to be done, by the Executive in good faith and in the best interests of the
Employer.

 

(b)Termination
by Executive. The Executive may terminate the Executive’s employment hereunder at any time.

 

(c)Termination
for Cause; Voluntary Termination. If the Executive is terminated by the Employer for Cause, or if the Executive voluntarily
terminates employment without Good Reason, then, except as required by law, the Employer shall have no further obligations with
respect to Executive’s employment hereunder or otherwise from and after the date of said termination, except (i) to pay the
Executive's Base Salary then in effect through the date of termination, (ii) to pay the Executive for unreimbursed expenses incurred
prior to such termination pursuant to Section 5, and (iii) to pay the Executive any other accrued but unpaid obligations
of the Executive (including the payment of accrued and unused vacation time) ((i) through (iii) collectively referred to herein
as the “Accrued Obligations”).

 

(d)Termination Without Cause;
or Termination for Good Reason. If the Executive is terminated by the Employer without Cause or if the Executive terminates
employment for “Good Reason” (as defined hereinbelow) at any time after November 1, 2013, the Executive shall be entitled
to receive, in addition to the Accrued Obligations, (i) severance in an amount equal to 100% of the Executive's Base Salary then
in effect, provided that such severance shall be paid to the Executive, net of payroll taxes and other deductions, over a twelve
(12) month period (the “Severance Period”), in accordance with the customary payroll practices of the Employer as in
effect on the Executive’s termination date, commencing as of such date subject to Section 6(g), (ii) the Executive’s
full bonus target for the twelve month period following such termination paid in equal installments over the Severance Period,
and (iii) automatic vesting of options that would otherwise fully vest during such twelve month period.

 

    	-4-

    	 

    

 

For purposes of this
Agreement, “Good Reason” shall mean, in the absence of a written consent of Executive:

 

  (i) the failure of the Employer to pay any material amounts due to the Executive or to fulfill any other material obligations to the Executive under this Agreement;; or

 

  (ii) a material reduction in the Executive’s Base Salary or/and target annual bonus, unless such reduction is not greater than the average percentage reduction in the base salary of other executive-level employees of the Employer.

 

(iii)
the Company’s transfer of Executive’s Place of Performance of services to a geographic location more than 50 miles
from the George Washington Bridge.

 

Any notice of termination for Good Reason
must be made no later than ninety (90) days following the initial existence of one or more of the above circumstances constituting
“Good Reason”, as defined above and shall be effective no later than twelve (12) months following such initial occurrence.
Notwithstanding the foregoing, in the event that Executive provides written notice of termination for Good Reason, the Company
shall have the opportunity to cure such circumstances within thirty (30) days of receipt of such notice. If Executive does not
deliver to the Company a notice of termination within the ninety (90) day period after Executive has knowledge that an event constituting
Good Reason has occurred, such event will no longer constitute Good Reason.

 

(e) Termination
During Probationary Period. Notwithstanding anything to the contrary set forth in this Agreement, if the Executive is
terminated by the Employer prior to November 1, 2013 by providing thirty (30) days prior written notice, the Employer shall have
no further obligations with respect to Executive’s employment hereunder or otherwise from and after the date of said termination,
except (i) to pay the Executive's Base Salary then in effect through the date of termination, (ii) to pay the Executive for unreimbursed
expenses incurred prior to such termination pursuant to Section 5, and (iii) to pay the Executive any Accrued Obligations.

 

(f) Termination in the Event of
Death or Disability Notwithstanding anything to the contrary set forth in this Agreement, the Employee's employment
under this Agreement shall terminate in the event of the Employee's death or disability. Disability shall mean the inability of
the Executive to perform substantial and material duties due to physical or mental disablement which continues for a period of
six (6) consecutive months during the employment term as determined by an independent qualified physician mutually acceptable to
the Company and the Executive, or his personal representative. If the Executive is terminated by reason of disability, the Executive's
Base Salary provided in Section 3(a) and the other benefits provided under Section 4 shall be continued on a monthly basis as in
effect on the Executive’s termination date, commencing as of such date subject to Section 6(g) until the waiting period for
payment of disability benefits prescribed in any long-term disability insurance provided by the Company to cover the Executive
for such disability is satisfied. In the event this Agreement should terminate by reason of death of the Executive, the Executive's
spouse (or the Executive's estate) shall be paid, upon the occurrence of such termination, applicable death benefits to which the
spouse is entitled under any existing benefit plans of the Company, plus one (1) year's Base Salary pursuant to the terms of this
Agreement, within thirty (30) days from the date of death.

 

    	-5-

    	 

    

 

(g)General Release.
Notwithstanding the foregoing, the Executive shall not be entitled to any payment or benefit pursuant to this Section 6
(except payment of the Accrued Obligations) unless the Executive executes (and does not revoke) within a prescribed period not
to exceed sixty (60) days from the date of termination, , a general release of the Employer and its affiliates, and their respective
officers, directors, employees and agents (the “Releasees”), in form and substance reasonably satisfactory to
the Employer.

 

7.Non-Solicitation
and Non-Competition.

 

(a)Non-Competition. The
Executive agrees that during the Restricted Period, the Executive will not (i) engage or participate, directly or indirectly, as
principal, agent, executive, director, proprietor, joint venturer, trustee, employee, employer, consultant, partner or in any other
capacity whatsoever, in the conduct or management of, or own any stock or any other equity investment in or debt of, or provide
any services of any nature whatsoever to or in respect of any business that is competitive with any business conducted or planned
by the Employer or any parent or subsidiaries thereof (collectively, the "PCA Entit(ies)") as of the date of termination
or within twelve (12) months prior to such date of termination (a "Competitive Business") or (ii) become an employee
of, consultant to or, in his or her individual capacity, an independent contractor to any current or targeted customer of any PCA
Entities as of or within twelve (12) months prior to the date of termination of the Executive's employment, provided that the Executive
may become such an employee, consultant or independent contractor of a current or targeted customer that is a multi-unit business
if the Executive is not employed or engaged to (A) provide any activity or service that would constitute a Competitive Business
or (B) be involved in the procurement, servicing or managing of any activity or services conducted or planned by any of the PCA
Entities as of the date of termination of the Executive's employment or within twelve (12) months prior to such date of termination,
provided further that nothing herein shall prevent the Executive from making passive investments constituting ownership of less
than two (2%) of any class of equity interest) in a publicly held corporation. For purposes of this Agreement, “Restricted
Period” means the period that the Executive is employed by the Employer or any Affiliate thereof and for a period of
twelve (12) months following termination, regardless of the reason for such termination.

 

(b)Non-Solicitation
of Employees. During the Restricted Period, the Executive will not, for the Executive's own benefit or for the benefit of any
Person other than the PCA Entities, (i) solicit, or assist any Person to solicit, any officer, director, executive or employee
of or consultant to any PCA Entity to leave his or her employment with or terminate his or her engagement by any PCA Entity , (ii)
hire or cause to be hired any Person who is then, or who at any time within the preceding twelve (12) months was, an officer, a
director, an executive or an employee of or consultant to any PCA Entity or (iii) engage any Person who is then or who at any time
within the preceding twelve (12) months was, an officer, director, executive or employee of or consultant to any PCA Entity as
a partner, contractor, sub-contractor or consultant or in any other capacity whatsoever; provided that the foregoing shall not
apply to any general solicitation (or hiring as a result thereof) directed to the general public of any Person holding (or who
last held) a position below the level of [director, manager or supervisor of an operational or sales business unit].

 

    	-6-

    	 

    

 

(c) Non-Solicitation
of Customers. During the Restricted Period, the Executive will not (i) solicit, or assist any Person other than an PCA Entity
to solicit, any Person that is a client or customer of any PCA Entity, or has been a client or customer of any PCA Entity during
the prior twelve (12) months, to provide any services relating to a Competitive Business or (ii) interfere with any of the business
relationships of any PCA Entity.

 

(d)Scope.
The Executive acknowledges that (i) the markets served by the PCA Entities are national and international in scope and are
not dependent on the geographic location of the executive personnel or the businesses by which they are employed; and (ii) the
above covenants are reasonable on their face, and the parties expressly agree that such restrictions have been designed to be reasonable
and no greater than is required for the protection of the PCA Entities and are a significant element of the consideration hereunder.

 

8.Confidential
Information.

 

(a)The Executive
shall not (for the Executive's own benefit or the benefit of any Person other than the PCA Entities) use or disclose any information
with respect to any PCA Entity or any customer or client of any PCA Entity (collectively, “Confidential Information”).
“Confidential Information” includes, by way of example, matters of a business nature, such as proprietary information
about costs, profits, markets, sales, lists of customers, and other information of a similar nature and matters of a technical
nature, “know-how,” computer programs (including documentation of such programs) and research projects, in each case,
to the extent not available to the public and to the extent not independently generated by the Executive or others without any
reference to the Confidential Information of any PCA Entity or any customer or client of an PCA Entity, and such materials constituting
plans for future development. Notwithstanding the foregoing, the Executive may disclose Confidential Information (i) if compelled
to disclose the same by judicial or administrative process or by other requirements of law or regulation (but subject to the following
provisions of this Section 9(a)), (ii) if the same hereafter is in the public domain through no fault of the Executive, (iii) if
the same is later acquired by the Executive from another source that is not under an obligation to another Person to keep such
information confidential or (iv) if the same was independently developed by the Executive without use of, or reference to, any
of the information furnished by or on behalf of any PCA Entity, provided that such independent development can reasonably be proven
by written records. If the Executive is requested or required (by oral questions, interrogatories, requests for information or
documents in legal proceedings, subpoena, civil investigative demand or other similar process) to disclose any such information,
the Executive shall provide the applicable PCA Entity with prompt written notice of any such request or requirement so that such
PCA Entity may seek a protective order or other appropriate remedy and/or waive compliance with the provisions of this Section
9(a). If, in the absence of a protective order or other remedy or the receipt of a waiver by the applicable PCA Entity, the Executive
nonetheless, based on the written advice of outside counsel, is required to disclose such information to any tribunal or in accordance
with applicable law or regulation, the Executive, without liability hereunder, may disclose that portion of such information which
such counsel advises the Executive he or she is legally required to disclose.

 

    	-7-

    	 

    

 

(b)At any time
upon the request of the Employer or any PCA Entity, the Executive (or the Executive's heirs or personal representatives) shall
deliver to the Employer or any other applicable PCA Entity all documents and materials containing Confidential Information and
all documents, materials and other property belonging to the Employer or such PCA Entity, which in either case are in the possession
or under the control of the Executive (or the Executive's heirs or personal representatives).

 

(c)All discoveries
and works made or conceived by the Executive during and in the course of the Executive's employment by the Employer, individually
or jointly with others, that relate to the Employer’s activities shall be owned and assignable by the Employer. The terms
“discoveries and works” include, by way of example, inventions, computer programs (including documentation of such
programs), technical improvements, processes, drawings, and works of authorship, including all publications which relate to the
business conducted by any of the PCA Entities or the business, operations or activities of any customer or client of the Employer.
The Executive shall promptly notify and make full disclosure to, and execute and deliver any documents reasonably requested by,
the Employer to evidence or confirm title to such discoveries and works by the Employer, assist the Employer in obtaining or maintaining,
at the Employer’s expense, United States and foreign patents, copyrights, trade secret protection and other protection of
any and all such discoveries and works, and promptly execute, whether during the Executive’s employment or thereafter, all
applications or other endorsements necessary or appropriate to maintain patents and other rights for the Employer or its assignees
and to protect its title thereto. Any discoveries and works which, within six months after the termination of the Executive’s
employment hereunder, are made, disclosed, reduced to a tangible or written form or description, or are reduced to practice by
the Executive and which pertain to work performed by the Executive while with, and in the Executive’s capacity as an employee
of, the Employer shall, as between the Executive and the Employer, be presumed to have been made during the Executive’s employment
by the Employer. The Executive hereby assigns to the Employer the Executive's interest, if any, in all discoveries and works made
or conceived by the Executive during and in the course of the Executive’s employment by the Sellers, individually or jointly
with others, that related to the Seller’s activities and agrees to comply with this Section 8(c) in relation to all such
discoveries and works.

 

    	-8-

    	 

    

 

9.Enforcement.

 

(a)The Executive
agrees that because a remedy at law may be inadequate to properly compensate the Employer from violations of Sections 7
and 8 and thus, injunctive relief may be necessary to affect the intent of such Sections. Accordingly, the Executive hereby waives
any objection to Employer’s attempts to seek injunctive relief as a remedy to the Executive’s breach of Section
7 or 8.

 

(b)In the event
that any court of competent jurisdiction shall determine that any one or more of the provisions contained in Sections 7
or 8 shall be unenforceable in any respect, then such provisions shall be deemed limited and restricted to the extent that the
court shall deem the provision to be enforceable. It is the intention of the parties to this Agreement that the covenants and restrictions
in Sections 7 or 8 be given the broadest interpretation permitted by law. The invalidity or unenforceability of any provision
of any provision therein shall not affect the validity or enforceability of any other provision hereof. If, in any judicial or
arbitration proceedings, a court of competent jurisdiction or arbitration panel should refuse to enforce all of the separate covenants
and restrictions in such Sections, then such unenforceable covenants and restrictions shall be eliminated from the provisions of
this Agreement for the purpose of such proceeding to the extent necessary to permit the remaining separate covenants and restrictions
to be enforced in such proceeding.

 

10.
Property of Employer.

 

The Executive acknowledges
that from time to time in the course of providing services pursuant to this Agreement, Executive shall have the opportunity to
inspect and use certain property, both tangible and intangible, of the Employer, and the Executive hereby agrees that such property
shall remain the exclusive property of the Employer and the Executive shall have no right or proprietary interest in such property,
whether tangible or intangible including, without limitation, the customer and supplier lists, contract forms, books of account,
computer programs and similar property of the Employer.

 

11.
Miscellaneous.

 

(a)Notices.
All notices required or permitted under this Agreement shall be in writing and shall be deemed effective upon personal delivery
by overnight courier or upon deposit with the United States Postal Service, by registered or certified mail, postage prepaid, addressed
to the other party at (i) in the case of the Employer, in care of Prescription Corporation of America, 66 Ford Road, Suite 230,
Denville, New Jersey 07834, with a copy to Thomas E. Durkin, III at Durkin & Durkin, 1120 Bloomfield Avenue, West Caldwell,
New Jersey and (ii) in the case of the Executive, at the address shown above, or at such other address or addresses as either party
shall designate to the other in writing from time to time.

 

(b)Gender.
Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter
forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa.

 

    	-9-

    	 

    

 

(c)Amendments;
Waiver. This Agreement shall not be amended, altered or modified except by an instrument in writing duly executed by the parties
hereto. Neither the waiver by either of the parties hereto of a breach of or a default under any of the provisions of this Agreement,
nor the failure of either of the parties, on one or more occasions, to enforce any of the provisions of this Agreement or to exercise
any right or privilege hereunder, shall thereafter be construed as a waiver of any subsequent breach or default of a similar nature,
or as a waiver of any such provisions, rights or privileges hereunder.

 

(d)Governing
Law. This Agreement shall be construed, interpreted and enforced in accordance with the laws of the State of New Jersey, without
the application of conflicts of law provisions thereof.

 

(e)Venue.
Any controversy, claim, or suit arising out of or relating to this Agreement or the employment relationship between the Executive
and the Employer, if not resolved between the parties, shall be submitted to any court of competent jurisdiction in the State of
New Jersey.

 

(f)Assignment.
The rights and obligations of the parties to this Agreement shall not be assignable or delegable, except that (i) in the event
of the Executive’s death, the personal representative or legatees or distributes of the Executive’s estate, as the
case may be, shall have the right to receive any amount owing and unpaid to the Executive hereunder and (ii) the rights and obligations
of the Company hereunder shall be assignable and delegable in connection with any subsequent merger, consolidation, sale of all
or substantially all of the assets or stock of the Company or similar transaction involving the Company or a successor corporation.

 

(g)Waivers.
No delays or omission by the Employer or the Executive in exercising any right under this Agreement shall operate as a waiver of
that or any other right. A waiver or consent given by the Employer or the Executive on any one occasion shall be effective only
in that instance and shall not be construed as a bar or waiver of any right on any other occasion.

 

(h)Headings.
The captions appearing in this Agreement are for convenience of reference only and in no way define, limit or affect the scope
or substance of any section of this Agreement.

 

(i) Enforceability.
In case any provision of this Agreement shall be held by a court with jurisdiction over the parties to this Agreement to be invalid,
illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected
or impaired thereby.

 

(j)Entire Agreement.
This instrument contains the entire agreement between the Parties with respect to the matters set forth herein and supersedes all
previous written, oral or implied understandings and agreements between the Parties with respect to such matters.

 

    	-10-

    	 

    

 

12.
Indemnification by Company.

 

The Company hereby indemnifies
and agrees to hold the Executive harmless from and against any and all damages, loss, liability, claim, cost, expense, action and
causes of action (including without limitation, reasonable attorney’s fees and disbursements) incurred by or asserted against
the Executive, arising from or in connection with any claims, liabilities, causes of action incurred or arising after the Effective
Date of this Agreement, as a result of any acts or omissions of the Executive in the performance of his duties hereunder to the
maximum extent permitted under the laws of the State of New Jersey. The Executive shall be covered by the Company’s Directors
& Officers insurance policy pursuant to and in accordance with the terms of such policy as same may be amended by the Company
from time to time.

 

13.Compliance
With Code Section 409A.

 

(a)Unless otherwise
otherwise expressly provided in writing, any payment of compensation by Company to the Executive, whether pursuant to this Agreement
or otherwise, shall be made no later than the 15th day of the third month (i.e. 21⁄2 months) after the end of the later of
the calendar year or the Company’s fiscal year in which the Executive’s right to such payment vests (i.e., is not subject
to a substantial risk of forfeiture for purposes of Internal Revenue Code Section 409A (“Code Section 409A”)). Such
amounts shall not be subject to the requirements of subsection (b) below applicable to “nonqualified deferred compensation.”

 

(b)All payments of
“nonqualified deferred compensation” (within the meaning of Code Section 409A are intended to comply with the requirements
of Code Section 409A, and shall be interpreted in accordance therewith. Neither party individually or in combination may accelerate,
offset or assign any such deferred payment, except in compliance with Code Section 409A. No amount shall be paid prior to the earliest
date on which it is permitted to be paid under Code Section 409A and Executive shall have no discretion with respect to the timing
of payments except as permitted under Section 409A. In the event that the Executive is determined to be a “specified employee”
(as defined and determined under Code Section 409A) of Company at a time when its stock is deemed to be publicly traded on an established
securities market, payments determined to be “nonqualified deferred compensation” payable by reason of “separation
from service” shall be paid no earlier than (i) the first day of the seventh (7th) calendar month commencing after such termination
of employment, or (ii) the Executive’s death, consistent with and to the extent necessary to meet the requirements Code Section
409A without the imposition of additional taxes. Any payment delayed by reason of the prior sentence shall be paid out in a single
lump sum on the earliest date permitted under Code Section 409A in order to catch up to the original payment schedule.

 

(c)For purposes of
this Agreement, termination of employment shall be deemed to occur only upon “separation from service” as such term
is defined under Code Section 409A. Each payment and each installment of any severance payments provided for under this Agreement
shall be treated as a separate payment for purposes of application of Code Section 409A. Section (b) above shall not apply to that
portion of any amounts payable upon termination of employment which shall qualify as “involuntary severance” under
Section 409A because such amount (i) does not exceed the lesser of (1) two hundred percent (200%) of the Executive’s annualized
compensation from the Company for the calendar year immediately preceding the calendar year during which the termination of employment
occurs, or (2) two hundred percent (200%) of the annual limitation amount under Section 401(a)(17) of the Code for the calendar
year during which termination of employment occurs (i.e. $510,000 in 2013), and (ii) is paid no later than the end of the second
calendar year commencing after termination of employment. Any Section 409A payments which are subject to execution of a waiver
and release which may be executed and/or revoked in a calendar year following the calendar year in which the payment event (such
as termination of employment) occurs shall commence payment only in the calendar year in which the release revocation period ends
as necessary to comply with Section 409A and any amounts delayed by reason of this provision shall be paid in a lump sum as soon
as permissible under Section 409A.

 

    	-11-

    	 

    

 

(d)All benefit plans,
programs and policies sponsored by the Company are intended to comply with all requirements of Code Section 409A or to be structured
so as to be exempt from the application of Code Section 409A. All expense reimbursement or in-kind benefits subject to Code 409A
which are provided under this Agreement or, unless otherwise specified in writing, under any Company program or policy shall be
subject to the following rules: (i) the amount of expenses eligible for reimbursement or in-kind benefits provided during one calendar
year may not affect the benefits provided during any other year; (ii) reimbursements shall be paid no later than the end of the
calendar year following the year in which the Executive incurs such expenses, and the Executive shall take all actions necessary
to claim all such reimbursements on a timely basis to permit the Company to make all such reimbursement payments prior to the end
of said period, and (iii) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another
benefit.

 

14.Counterparts:

 

This Agreement may
be executed in any number of counterparts and by different parties on separate counterparts, each of which counterparts, when so
executed and delivered, shall be deemed to be an original and all of which counterparts, taken together, shall constitute but one
and the same Agreement. This Agreement shall become effective upon the execution and delivery of a counterpart hereof by each of
the parties hereto. Delivery by telecopier or by electronic or digital transmission in PDF format of an executed counterpart of
a signature page to this Agreement or any notice, communication, agreement, certificate, document or other instrument in connection
herewith shall be effective as delivery of an executed original counterpart thereof. 

 

 

[SIGNATURE PAGE FOLLOWS]

 

 

 

 

    	-12-

    	 

    

 

IN WITNESS WHEREOF,
the parties have executed this Agreement as of the day and year first above written.

 

	 	PRESCRIPTION CORPORATION OF AMERICA
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Gary
    Sekulski
	 	 	Name:	Gary Sekulski
	 	 	Title:	Chief Executive Officer
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	EXECUTIVE:
	 	 	 	 
	 	/s/ Yoram Bibring
	 	Yoram Bibring

 

 

    	-13-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]